Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Is there a vaccination waiting period after cosentyx?Is a doctor's consultation needed before combining lipitor and herbal supplements?When will trintellix go generic?Can ginseng affect lipitor's effectiveness?Can you name lipitor's binding sites on hmg coa reductase?
See the DrugPatentWatch profile for sancuso
What is Sancuso? Sancuso is an onapristone, fentanyl transdermal patch, used for the management of chemotherapy-induced nausea and vomiting (CINV) in adult cancer patients receiving highly and moderately emetogenic chemotherapy [1]. The patch is placed on the stomach or lower back, providing a continuous delivery of opioid medication to help alleviate symptoms of nausea and vomiting [1]. Is Sancuso a traditional transdermal patch? Sancuso is a single-use, pre-activated, adhesive transdermal patch [1]. The patch is not a traditional transdermal patch in the sense that it is not a passive, static delivery system. Instead, Sancuso utilizes an active ion-transport mechanism to drive the release of onapristone, fentanyl, and additional ingredients [1] throughout the 72-hour treatment duration. This active system aims to enhance and maintain steady-state plasma concentrations of the active ingredients. Key differences from traditional patches Sancuso has an additional component of onapristone, which is a selective progesterone receptor modulator (SPRM). This ingredient is used in combination with fentanyl to target and reduce chemotherapy-induced emesis. Traditional transdermal patches primarily rely on the sustained release of their active pharmaceutical ingredients [2]. Comparison with other transdermal patches Sancuso is not equivalent to other popular transdermal fentanyl patches, such as Duragesic, which require activation before use. Sancuso is specifically designed for the management of CINV, providing a unique combination of onapristone and fentanyl in a single-use patch. Patent information The Sancuso patent, assigned to DureCT Corporation, expires in 2025 [${index} 3]. The patent protection covers the composition, formulation, and delivery mechanism of Sancuso [${index} 3]. References: [1] Sancuso [Package Insert]. [2] Wikipedia - Transdermal patch (2023). [3] DrugPatentWatch. (n.d.). Sancuso Patent Information. Retrieved from https://www.drugpatentreports.com/patentreport/patent/US10144411B2
Other Questions About Sancuso :